RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
Throughout the 2 pivotal trials, RINVOQ delivered speedy and significant illness management with almost half of ankylosing spondylitis (AS) sufferers reaching ...
